Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.

Dykens EM, Miller J, Angulo M, Roof E, Reidy M, Hatoum HT, Willey R, Bolton G, Korner P

JCI insight21 Jun 2018Cited by 69 (Europe PMC)

PMID29925684PMCIDPMC6124421DOI10.1172/jci.insight.98333PepBankPUB-29925684

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome
In adolescents with Prader-Willi syndrome, intranasal carbetocin, an oxytocin analog, reduced the HPWSQ-R hyperphagia total score more than placebo.
In plain wordsIn adolescents with Prader-Willi syndrome, nasal carbetocin, a drug related to oxytocin, reduced hyperphagia scores more than placebo.
Peptide
Oxytocin
Outcome
DecreaseHPWSQ-R total score change at study end
Study
n = 37
Comparator
Placebo
Analysis
Primary
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
HPWSQ-R total score change
−15.6 points
carbetocin
HPWSQ-R total score change
−8.9 points
placebo
Source sentences
Summary
Patients receiving carbetocin had statistically significant reductions in HPWSQ-R total score at study end (-15.6) versus patients receiving placebo (-8.9; P = 0.029); several secondary efficacy endpoints also demonstrated significant differences (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2992568401
02HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome
In adolescents with Prader-Willi syndrome, intranasal carbetocin, an oxytocin analog, produced significant differences versus placebo in several secondary efficacy endpoints.
In plain wordsIn adolescents with Prader-Willi syndrome, nasal carbetocin, a drug related to oxytocin, beat placebo on several secondary measures.
Peptide
Oxytocin
Outcome
DecreaseSecondary efficacy endpoints
Study
n = 37
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
several secondary efficacy endpoints also demonstrated significant differences (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2992568402
03HumanNot a test of Oxytocin aloneRandomized controlled trialMechanism
In adolescents with Prader-Willi syndrome treated with carbetocin or placebo, treatment effects on the primary and secondary endpoints were highly correlated.
In plain wordsIn adolescents with Prader-Willi syndrome, the effects of nasal carbetocin, a drug related to oxytocin, on the main and secondary measures moved together.
Peptide
Oxytocin
Outcome
Not applicableCorrelation of primary and secondary endpoint effects
Study
n = 37
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Treatment effects for the primary and secondary endpoints were highly correlated (P ≤ 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2992568403
04HumanNot a test of Oxytocin aloneRandomized controlled trialSafety outcome
In adolescents with Prader-Willi syndrome, the incidence of adverse events was similar between intranasal carbetocin, an oxytocin analog, and placebo.
In plain wordsIn adolescents with Prader-Willi syndrome, nasal carbetocin, a drug related to oxytocin, had side-effect rates similar to placebo.
Peptide
Oxytocin
Outcome
No significant changeIncidence of adverse events
Study
n = 37
Comparator
Placebo
Outcome group
Adverse events · Whole body
Source sentences
Summary
Incidence of adverse events (AEs) was similar between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2992568404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:51 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.